R-Pharm’s production of finished dosage forms in Yaroslavl is designed with account to all latest GMP requirements, which is unprecedented for Russia, especially for the production of aseptic injection drug formulations. Within the project, the company will produce drugs for treatment of most important vital diseases, such as diabetes mellitus, virus hepatitises, HIV infection, heavy bacterial and fungal infections, oncological diseases, rheumatoid arthritis, etc.
R-Pharm’ site is a part of pharmaceutical cluster of Yaroslavl region. The company invested over 2,5 billion Rubles (over $80 million) into the first stage of manufacturing project in Yaroslavl. Second stage development plan - over 3 billion Rubles ($100 million) investments.
Processes, equipment, sterile areas and sites of the factory were qualified and validated according to the requirements of the GMP standard, recently passed audits by multinational pharmaceutical companies: Astellas Pharma, AstraZeneca, Eli Lilly, Johnson & Johnson, Pfizer, Merck and others.